Please try another search
For the fiscal year ended 31 December 2019, XynomicPharmaceuticals Holdings Inc revenues was not reported. Netloss applicable to common stockholders increased from $738Kto $26.8M. Higher net loss reflects Interest incomedecrease of 100% to $3K (income). Basic Earnings per Shareexcluding Extraordinary Items decreased from -$0.30 to-$0.83.
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.92 | -4.96 | -3.03 | -14.13 |
Net Income | -2.93 | -4.98 | -3.05 | -14.14 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Assets | 0.94 | 0.74 | 2.01 | 8.5 |
Total Liabilities | 23.5 | 20.59 | 17.05 | 0.84 |
Total Equity | -22.56 | -19.85 | -15.04 | 7.66 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -10.67 | -9.17 | -7.98 | -0.13 |
Cash From Investing Activities | 63.26 | 63.28 | 63.26 | 55.18 |
Cash From Financing Activities | -57.22 | -58.82 | -58.86 | -55.17 |
Net Change in Cash | -4.65 | -4.72 | -3.55 | -0.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review